BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384. [PMID: 15306603 DOI: 10.1136/gut.2003.022111] [Cited by in Crossref: 543] [Cited by in F6Publishing: 528] [Article Influence: 31.9] [Reference Citation Analysis]
Number Citing Articles
1 Raj R, Agarwal N, Raghavan S, Chakraborti T, Poluri KM, Kumar D. Exquisite binding interaction of 18β-Glycyrrhetinic acid with histone like DNA binding protein of Helicobacter pylori: A computational and experimental study. International Journal of Biological Macromolecules 2020;161:231-46. [DOI: 10.1016/j.ijbiomac.2020.06.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
2 Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Adv Ther 2016;33:1140-57. [DOI: 10.1007/s12325-016-0345-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 7.4] [Reference Citation Analysis]
4 Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. World J Gastroenterol 2012;18:4542-8. [PMID: 22969227 DOI: 10.3748/wjg.v18.i33.4542] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:1338-1345. [PMID: 25867718 DOI: 10.1111/jgh.12984] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
6 Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol. 2016;22:3150-3157. [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
7 Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-496. [PMID: 16542284 DOI: 10.1111/j.1572-0241.2006.00637.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 171] [Article Influence: 12.3] [Reference Citation Analysis]
8 O'connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, O’connor H, Qasim A, Breslin N, O’moráin C. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol. 2010;22:1123-1127. [PMID: 20354442 DOI: 10.1097/meg.0b013e328338e43d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
9 Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK, Gareayaghi N, Ergin S, Erzin YZ, Bal K, Tascı İ, Tokman HB. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol 2019;68:566-73. [PMID: 30724729 DOI: 10.1099/jmm.0.000944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011;16:146-152. [PMID: 21435093 DOI: 10.1111/j.1523-5378.2011.00829.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
11 Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013;26:1222-1227. [PMID: 23579617 DOI: 10.1038/modpathol.2013.48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
12 Han KD, Matsuura A, Ahn HC, Kwon AR, Min YH, Park HJ, Won HS, Park SJ, Kim DY, Lee BJ. Functional identification of toxin-antitoxin molecules from Helicobacter pylori 26695 and structural elucidation of the molecular interactions. J Biol Chem 2011;286:4842-53. [PMID: 21123184 DOI: 10.1074/jbc.M109.097840] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
13 Heo J, Jeon SW, Jung JT, Kwon JG, Kim EY, Lee DW, Seo HE, Ha CY, Kim HJ, Kim ES, Park KS, Cho KB, Lee SH, Jang BI; Daegu-Gyeongbuk Gastrointestinal Study Group. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis. 2014;46:980-984. [PMID: 25132282 DOI: 10.1016/j.dld.2014.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
14 Xuan SH, Wu LP, Zhou YG, Xiao MB. Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review. J Glob Antimicrob Resist 2016;4:35-41. [PMID: 27436390 DOI: 10.1016/j.jgar.2016.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
15 Vale FF, Vadivelu J, Oleastro M, Breurec S, Engstrand L, Perets TT, Mégraud F, Lehours P. Dormant phages of Helicobacter pylori reveal distinct populations in Europe. Sci Rep 2015;5:14333. [PMID: 26387443 DOI: 10.1038/srep14333] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
16 Melake NA, Shaker GH, Salama MA. Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies. Saudi Pharm J. 2012;20:345-353. [PMID: 23960809 DOI: 10.1016/j.jsps.2012.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Cerqueira RM, Manso MC, Correia MR, Fernandes CD, Vilar H, Nora M, Martins P. Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days? Obes Surg. 2011;21:1377-1381. [PMID: 20838918 DOI: 10.1007/s11695-010-0254-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zaman C, Osaki T, Hanawa T, Yonezawa H, Kurata S, Kamiya S. Analysis of the microbial ecology between Helicobacter pylori and the gastric microbiota of Mongolian gerbils. J Med Microbiol 2014;63:129-37. [PMID: 24164959 DOI: 10.1099/jmm.0.061135-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
19 Epstein TD, Wu B, Moulton KD, Yan M, Dube DH. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen Helicobacter pylori. ACS Infect Dis 2019;5:1682-7. [PMID: 31487153 DOI: 10.1021/acsinfecdis.9b00251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
20 Wu T, Wang L, Gong M, Lin Y, Xu Y, Ye L, Yu X, Liu J, Liu J, He S, Zeng H, Wang G. Synergistic effects of nanoparticle heating and amoxicillin on H. pylori inhibition. Journal of Magnetism and Magnetic Materials 2019;485:95-104. [DOI: 10.1016/j.jmmm.2019.04.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. J Antimicrob Chemother 2019;74:1069-77. [PMID: 30668729 DOI: 10.1093/jac/dky510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
22 Mégraud F. Time to change approaches to Helicobacter pylori management. Lancet Gastroenterol Hepatol 2017;2:692-3. [PMID: 28781120 DOI: 10.1016/S2468-1253(17)30245-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Manyi-Loh CE, Clarke AM, Munzhelele T, Green E, Mkwetshana NF, Ndip RN. Selected South African honeys and their extracts possess in vitro anti-Helicobacter pylori activity. Arch Med Res. 2010;41:324-331. [PMID: 20851288 DOI: 10.1016/j.arcmed.2010.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
24 Gallardo Padilla M, León Falconi JL, Sánchez-Nebreda Arias R, Gómez Santos C, Muñoz Egea MDC, la Orden Izquierdo E. [Impact of the use of molecular techniques (PCR) on detection and eradication success against Helicobacter pylori]. An Pediatr (Engl Ed) 2021:S1695-4033(20)30502-6. [PMID: 33431330 DOI: 10.1016/j.anpedi.2020.11.016] [Reference Citation Analysis]
25 Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013;18:180-186. [PMID: 23305083 DOI: 10.1111/hel.12034] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
26 Snelling WJ, Moran AP, Ryan KA, Scully P, McGourty K, Cooney JC, Annuk H, O'Toole PW. HorB (HP0127) is a gastric epithelial cell adhesin. Helicobacter. 2007;12:200-209. [PMID: 17492999 DOI: 10.1111/j.1523-5378.2007.00499.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
27 Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, Talley NJ, Engstrand L, Agréus L. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11:224-230. [PMID: 16882324 DOI: 10.1111/j.1523-5378.2006.00414.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
28 Chen D, Cunningham SA, Cole NC, Kohner PC, Mandrekar JN, Patel R. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. Antimicrob Agents Chemother 2017;61:e02530-16. [PMID: 28167563 DOI: 10.1128/AAC.02530-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
29 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
30 Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol. 2009;24:1155-1157. [PMID: 19682186 DOI: 10.1111/j.1440-1746.2009.05911.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
31 De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Panella C, Vaira D. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother. 2010;65:327-332. [PMID: 20008044 DOI: 10.1093/jac/dkp445] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
32 Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56-65. [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
33 Li Y, Rimbara E, Thirumurthi S, Trespalacios A, Reddy R, Sabounchi S, Attumi TA, Graham DY. Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis. 2012;13:54-59. [PMID: 22188917 DOI: 10.1111/j.1751-2980.2011.00549.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
34 Liu Z, Shen J, Zhang L, Shen L, Li Q, Zhang B, Zhou J, Gu L, Feng G, Ma J, You WC, Deng D. Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history. BMC Microbiol 2008;8:81. [PMID: 18507832 DOI: 10.1186/1471-2180-8-81] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
35 Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens M, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013;19:379-83. [DOI: 10.1111/j.1469-0691.2012.03844.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
36 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017;23:2854-69. [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
37 Raj R, Agarwal N, Raghavan S, Chakraborti T, Poluri KM, Pande G, Kumar D. Epigallocatechin Gallate with Potent Anti-Helicobacter pylori Activity Binds Efficiently to Its Histone-like DNA Binding Protein. ACS Omega 2021;6:3548-70. [PMID: 33585739 DOI: 10.1021/acsomega.0c04763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pylori. World J Gastroenterol. 2014;20:8947-8956. [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571-1581. [PMID: 17845685 DOI: 10.1111/j.1440-1746.2007.05082.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
40 Agah S, Shazad B, Abbaszadeh B. Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol. 2009;15:225-228. [PMID: 19794266 DOI: 10.4103/1319-3767.56091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
41 Egan BJ, Katicic M, O'Connor HJ, O'Morain CA. Treatment of Helicobacter pylori. Helicobacter. 2007;12 Suppl 1:31-37. [PMID: 17727458 DOI: 10.1111/j.1523-5378.2007.00538.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
42 Gisbert JP, Pajares JM. Treatment of Helicobacter pylori infection: The past and the future. European Journal of Internal Medicine 2010;21:357-9. [DOI: 10.1016/j.ejim.2010.07.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
43 Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori. World J Gastroenterol. 2014;20:5594-5609. [PMID: 24914319 DOI: 10.3748/wjg.v20.i19.5594] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
44 Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, Dai WQ, Wang F, Shen M, Cheng P. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014;20:18013-18021. [PMID: 25548501 DOI: 10.3748/wjg.v20.i47.18013] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
45 Zhou Y, Taylor B, Smith TJ, Liu Z, Clench M, Davies NW, Rainsford KD. A novel compound from celery seed with a bactericidal effect against Helicobacter pylori. Journal of Pharmacy and Pharmacology 2009;61:1067-77. [DOI: 10.1211/jpp.61.08.0011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
46 Atapoor S, Safarpoor Dehkordi F, Rahimi E. Detection of Helicobacter pylori in Various Types of Vegetables and Salads. Jundishapur J Microbiol. 2014;7:e10013. [PMID: 25147709 DOI: 10.5812/jjm.10013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
47 Peura DA, Crowe SE. Helicobacter pylori. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 833-843.e4. [DOI: 10.1016/b978-1-4160-6189-2.00050-0] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
48 Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, Wang HM, Lai KH, Cheng JS, Chen A. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore). 2015;94:e2104. [PMID: 26632893 DOI: 10.1097/md.0000000000002104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
49 Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48:3703-3707. [PMID: 20668128 DOI: 10.1128/jcm.00144-10] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 6.9] [Reference Citation Analysis]
50 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357. [PMID: 17566020 DOI: 10.1136/gut.2007.125658] [Cited by in Crossref: 201] [Cited by in F6Publishing: 178] [Article Influence: 14.4] [Reference Citation Analysis]
51 De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Panella C, Vaira D. The A2143G point mutation of clarithromycin resistance affects Helicobacter pylori eradication. J Clin Gastroenterol. 2009;43:386. [PMID: 19077730 DOI: 10.1097/mcg.0b013e318178d1e7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, Maino M, Comparato G, Fanigliulo L, Morana E. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter. 2007;12:238-243. [PMID: 17493004 DOI: 10.1111/j.1523-5378.2007.00497.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
53 Chung WC, Jeon EJ, Oh JH, Park JM, Kim TH, Cheung DY, Kim BW, Kim SS, Kim JI. Dual-priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of Helicobacter pylori in bleeding peptic ulcers. Dig Liver Dis 2016;48:899-903. [PMID: 27211882 DOI: 10.1016/j.dld.2016.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
54 Pathak A, Blair VL, Ferrero RL, Mehring M, Andrews PC. Bismuth( iii ) benzohydroxamates: powerful anti-bacterial activity against Helicobacter pylori and hydrolysis to a unique Bi 34 oxido-cluster [Bi 34 O 22 (BHA) 22 ( H -BHA) 14 (DMSO) 6 ]. Chem Commun 2014;50:15232-4. [DOI: 10.1039/c4cc07329k] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 3.9] [Reference Citation Analysis]
55 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017;5:23. [PMID: 28702193 DOI: 10.1186/s40364-017-0103-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
56 Alazmi WM, Buhaimed W, Al-mekhaizeem K, Siddique I. Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait. Dig Dis Sci 2010;55:3120-3. [DOI: 10.1007/s10620-010-1139-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;6:183-198. [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
58 Rohdewald P, Beil W. In vitro inhibition ofHelicobacter pylori growth and adherence to gastric mucosal cells by Pycnogenol®. Phytother Res 2008;22:685-8. [DOI: 10.1002/ptr.2409] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
59 Boyanova L, Nikolov R, Lazarova E, Gergova G, Katsarov N, Kamburov V, Spassova Z, Derejian S, Jelev C, Mitov I, Krastev Z. Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. Journal of Medical Microbiology 2006;55:65-8. [DOI: 10.1099/jmm.0.46208-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
60 Qasim A, O’morain CA, O’connor HJ. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundamental & Clinical Pharmacology 2009;23:43-52. [DOI: 10.1111/j.1472-8206.2008.00635.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter. 2012;17:264-268. [PMID: 22759325 DOI: 10.1111/j.1523-5378.2012.00946.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
62 Manfredi M, Gismondi P, Maffini V, Bizzarri B, Fornaroli F, Madia C, Salerno A, Cangelosi AM, de'Angelis GL. Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy. Gastroenterol Res Pract 2015;2015:717349. [PMID: 26064096 DOI: 10.1155/2015/717349] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
63 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
64 Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010;29:1369-1375. [PMID: 20658256 DOI: 10.1007/s10096-010-1009-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
65 Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther 2017;24:e751-7. [PMID: 26808355 DOI: 10.1097/MJT.0000000000000389] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 8.7] [Reference Citation Analysis]
66 Ramos-Soriano AG, Black J. Nitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori Infection. Case Rep Gastroenterol 2015;9:36-42. [PMID: 25759631 DOI: 10.1159/000375116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
67 Fang WJ, Zhang XY, Yang B, Sui SJ, Chen M, Pan WH, Liao WQ, Zhong M, Wang QC. CHINESE HERBAL DECOCTION AS A COMPLEMENTARY THERAPY FOR ATROPHIC GASTRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Afr J Tradit Complement Altern Med 2017;14:297-319. [PMID: 28638893 DOI: 10.21010/ajtcam.v14i4.33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol. 2012;18:4386-4390. [PMID: 22969203 DOI: 10.3748/wjg.v18.i32.4386] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
69 Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146-1154. [PMID: 28315035 DOI: 10.1007/s10620-017-4536-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
70 Huang HL, Ko CH, Yan YY, Wang CK. Antiadhesion and anti-inflammation effects of noni (Morinda citrifolia) fruit extracts on AGS cells during Helicobacter pylori infection. J Agric Food Chem 2014;62:2374-83. [PMID: 24528133 DOI: 10.1021/jf405199w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
71 Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf. 2014;23:443-455. [PMID: 24677603 DOI: 10.1002/pds.3581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
72 Yilmaz O, Demiray E, Tümer S, Altungöz O, Yörükoğlu K, Soytürk M, Simşek I. Detection of Helicobacter pylori and determination of clarithromycin susceptibility using formalin-fixed, paraffin-embedded gastric biopsy specimens by fluorescence in situ hybridization. Helicobacter 2007;12:136-41. [PMID: 17309750 DOI: 10.1111/j.1523-5378.2007.00483.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
73 Baroni MR, Bucci P, Giani RN, Giusti A, Tedeschi FA, Salvatierra E, Barbaglia Y, Jimenez F, Zalazar FE. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Revista Argentina de Microbiología 2018;50:359-64. [DOI: 10.1016/j.ram.2017.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
74 Kalach N, Serhal L, Asmar E, Campeotto F, Bergeret M, Dehecq E, Spyckerelle C, Charkaluk ML, Decoster A, Dupont C. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis. 2007;59:217-222. [PMID: 17662555 DOI: 10.1016/j.diagmicrobio.2007.05.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
75 Zhang L, Mei Q, Li QS, Hu YM, Xu JM. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people: CYP2C19 and IL-1 genotypes in H. pylori cure rate. Journal of Clinical Pharmacy and Therapeutics 2010;35:713-22. [DOI: 10.1111/j.1365-2710.2009.01140.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
76 Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! J Clin Gastroenterol. 2012;46:259-261. [PMID: 22395061 DOI: 10.1097/mcg.0b013e318247177e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
77 Shahidzadeh R, Opekun A, Shiotani A, Graham DY. Effect of the Carbonic Anhydrase Inhibitor, Acetazolamide, on Helicobacter pylori Infection in vivo: A Pilot Study. Helicobacter 2005;10:136-8. [DOI: 10.1111/j.1523-5378.2005.00306.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
78 Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005;10:363-372. [PMID: 16181345 DOI: 10.1111/j.1523-5378.2005.00324.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
79 Secka O, Berg DE, Antonio M, Corrah T, Tapgun M, Walton R, Thomas V, Galano JJ, Sancho J, Adegbola RA, Thomas JE. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. Antimicrob Agents Chemother. 2013;57:1231-1237. [PMID: 23263004 DOI: 10.1128/aac.00517-12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
80 Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, Pilloni AP, Tufano MA, Vaira D, Nardone G. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol. 2008;61:1112-1115. [PMID: 18755715 DOI: 10.1136/jcp.2008.060392] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
81 Kang BK, Park SM, Kim BW. [New therapeutic strategies against Helicobacter pylori]. Korean J Gastroenterol 2014;63:146-50. [PMID: 24651587 DOI: 10.4166/kjg.2014.63.3.146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Jung SW, Thamphiwatana S, Zhang L, Obonyo M. Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori. PLoS One. 2015;10:e0116519. [PMID: 25793403 DOI: 10.1371/journal.pone.0116519] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
83 O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, Basset C. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol. 2005;11:7499-7507. [PMID: 16437723 DOI: 10.3748/wjg.v11.i47.7499] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
84 Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, Yin S. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res. 2013;46:607-613. [PMID: 23903685 DOI: 10.1590/1414-431x20132817] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
85 Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol 2011;2:35-41. [PMID: 21860834 DOI: 10.4291/wjgp.v2.i3.35] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
86 Chiesa C, Pacifico L, Anania C, Poggiogalle E, Chiarelli F, Osborn JF. Helicobacter pylori therapy in children: overview and challenges. Int J Immunopathol Pharmacol 2010;23:405-16. [PMID: 20646336 DOI: 10.1177/039463201002300203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
87 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
88 Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori Properties of Gut Gard. Prev Nutr Food Sci. 2013;18:104-110. [PMID: 24471118 DOI: 10.3746/pnf.2013.18.2.104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
89 Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol. 2011;49:3638-3643. [PMID: 21813726 DOI: 10.1128/jcm.01067-11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
90 Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.9] [Reference Citation Analysis]
91 Bytzer P, O'morain C. Treatment of Helicobacter pylori. Helicobacter 2005;10:40-6. [DOI: 10.1111/j.1523-5378.2005.00333.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
92 Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011;16:241-245. [PMID: 21585611 DOI: 10.1111/j.1523-5378.2011.00841.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
93 Cerqueira RM, Correia MR, Fernandes CD, Vilar H, Manso MC. Cumulative Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery. OBES SURG 2013;23:145-9. [DOI: 10.1007/s11695-012-0747-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
94 Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24. [DOI: 10.1111/hel.12606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Tanih NF, Ndip LM, Ndip RN. Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori. Ann Trop Med Parasitol 2011;105:251-9. [PMID: 21801504 DOI: 10.1179/136485911X12899838683485] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
96 Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol. 2012;18:6628-6634. [PMID: 23236238 DOI: 10.3748/wjg.v18.i45.6628] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
97 Ahmad N, Zakaria WR, Abdullah SA, Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J Gastroenterol 2009;15:3161-5. [PMID: 19575497 DOI: 10.3748/wjg.15.3161] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
98 Roccarina D, Franceschi F, Zocco MA, Garcovich M, Gasbarrini G, Gasbarrini A. Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis 2012;44:889-92. [PMID: 22743557 DOI: 10.1016/j.dld.2012.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
99 Alvarez A, Moncayo JI, Santacruz JJ, Santacoloma M, Corredor LF, Reinosa E. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob Agents Chemother 2009;53:4022-4. [PMID: 19546360 DOI: 10.1128/AAC.00145-09] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
100 Delchier JC. [Recommendations for the management of Helicobacter pylori infection according to Maastricht 3 guidelines]. Gastroenterol Clin Biol 2006;30:1361-4. [PMID: 17211333 DOI: 10.1016/s0399-8320(06)73555-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
101 Chua EG, Verbrugghe P, Perkins TT, Tay CY. Fucoidans Disrupt Adherence of Helicobacter pylori to AGS Cells In Vitro. Evid Based Complement Alternat Med 2015;2015:120981. [PMID: 26604968 DOI: 10.1155/2015/120981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
102 Giordano A, Cito L. Advances in gastric cancer prevention. World J Clin Oncol. 2012;3:128-136. [PMID: 23061031 DOI: 10.5306/wjco.v3.i9.128] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
103 Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux PA, Vasseur P, Thiebault Q, Lefèvre C, de Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C. Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay. J Clin Microbiol 2020;58:e01787-19. [PMID: 31996442 DOI: 10.1128/JCM.01787-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 17.0] [Reference Citation Analysis]
104 Auesomwang C, Maneerattanaporn M, Chey WD, Kiratisin P, Leelakusolwong S, Tanwandee T. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2018;33:1822-1828. [PMID: 29804294 DOI: 10.1111/jgh.14292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354-361. [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
106 Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia. Saudi J Gastroenterol 2014;20:212-8. [PMID: 25038206 DOI: 10.4103/1319-3767.136935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
107 Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, Kobayashi I. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009;53:3097-3099. [PMID: 19380599 DOI: 10.1128/aac.01552-08] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
108 Hulten KG, Genta RM, Kalfus IN, Zhou Y, Zhang H, Graham DY. Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology 2021:S0016-5085(21)03246-7. [PMID: 34293298 DOI: 10.1053/j.gastro.2021.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Tongtawee T, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Leeanansaksiri W, Loyd RA, Matrakool L, Panpimanmas S. Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand. Gastroenterol Res Pract 2016;2016:9130602. [PMID: 27042174 DOI: 10.1155/2016/9130602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Kumar BS, Tiwari SK, Manoj G, Kunwar A, Amrita N, Sivaram G, Abid Z, Ahmad A, Khan AA, Priyadarsini KI. Anti-unlcer and antimicrobial activities of sodium selenite against Helicobacter pylori: In vitro and in vivo evaluation. Scandinavian Journal of Infectious Diseases 2010;42:266-74. [DOI: 10.3109/00365540903493707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
111 Gao Y, Tang W, Gao H, Chan E, Lan J, Li X, Zhou S. Antimicrobial Activity of the Medicinal Mushroom Ganoderma. Food Reviews International 2007;21:211-29. [DOI: 10.1081/fri-200051893] [Cited by in Crossref: 33] [Article Influence: 2.4] [Reference Citation Analysis]
112 Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol. 2013;19:8168-8180. [PMID: 24363506 DOI: 10.3748] [Reference Citation Analysis]
113 Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010;44:536-543. [PMID: 20179610 DOI: 10.1097/mcg.0b013e3181d04592] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
114 Park JS, Park JE, Oh BS, Yoon BW, Kim HK, Lee JW, Kim NH, Cho WS, Woo YS, Jahng J, Kim YS. [Trend in the Eradication Rates of Helicobacter pylori Infection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience]. Korean J Gastroenterol 2017;70:232-8. [PMID: 29161792 DOI: 10.4166/kjg.2017.70.5.232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
115 Lim SG, Park RW, Shin SJ, Yoon D, Kang JK, Hwang JC, Kim SS, Kim JH, Lee KM. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016;48:385-90. [PMID: 26856963 DOI: 10.1016/j.dld.2015.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
116 Ortiz V, Estevez-Ordonez D, Montalvan-Sanchez E, Urrutia-Argueta S, Israel D, Krishna US, Romero-Gallo J, Wilson KT, Peek RM, Dominguez R, Morgan DR. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting. Helicobacter 2019;24:e12595. [PMID: 31111610 DOI: 10.1111/hel.12595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
117 Sundquist M, Quiding-Järbrink M. Helicobacter pylori and its effect on innate and adaptive immunity: new insights and vaccination strategies. Expert Rev Gastroenterol Hepatol. 2010;4:733-744. [PMID: 21108593 DOI: 10.1586/egh.10.71] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
118 Vakil N, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. J Clin Gastroenterol. 2013;47:383-388. [PMID: 23388847 DOI: 10.1097/mcg.0b013e318277577b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
119 Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? World J Gastroenterol. 2017;23:2453-2458. [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
120 Seo JH, Woo HO, Youn HS, Rhee KH. Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection. Korean J Pediatr. 2014;57:67-71. [PMID: 24678329 DOI: 10.3345/kjp.2014.57.2.67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
121 Zhou YQ, Xu L, Wang BF, Fan XM, Wu JY, Wang CY, Guo CY, Xu XF. Modified Sequential Therapy Regimen versus Conventional Triple Therapy for Helicobacter Pylori Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study. Gastroenterol Res Pract. 2012;2012:405425. [PMID: 22550478 DOI: 10.1155/2012/405425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
122 Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88. [DOI: 10.1038/nrgastro.2010.210] [Cited by in Crossref: 122] [Cited by in F6Publishing: 122] [Article Influence: 12.2] [Reference Citation Analysis]
123 Puram S, Suh HC, Kim SU, Bethapudi B, Joseph JA, Agarwal A, Kudiganti V. Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study. Evid Based Complement Alternat Med. 2013;2013:263805. [PMID: 23606875 DOI: 10.1155/2013/263805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
124 Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016;21:375-81. [PMID: 26807668 DOI: 10.1111/hel.12296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
125 Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007;25:1429-1434. [PMID: 17539982 DOI: 10.1111/j.1365-2036.2007.03331.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
126 Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, Wang W, Zhan YQ, Li W. Relationship between H.Pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer 2010;10:374. [PMID: 20637122 DOI: 10.1186/1471-2407-10-374] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
127 Jaka H, Rhee JA, Östlundh L, Smart L, Peck R, Mueller A, Kasang C, Mshana SE. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC Infect Dis 2018;18:193. [PMID: 29699490 DOI: 10.1186/s12879-018-3099-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
128 Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter. 2015;20:390-396. [PMID: 25801708 DOI: 10.1111/hel.12209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
129 Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter. 2012;17:36-42. [PMID: 22221614 DOI: 10.1111/j.1523-5378.2011.00912.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
130 Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore) 2016;95:e2698. [PMID: 26986096 DOI: 10.1097/MD.0000000000002698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
131 Cavallaro LG, Egan B, O’Morain C, Di Mario F. Treatment of Helicobacter pylori infection. Helicobacter. 2006;11 Suppl 1:36-39. [PMID: 16925610 DOI: 10.1111/j.1478-405x.2006.00428.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
132 Mégraud F, Bénéjat L, Ontsira Ngoyi EN, Lehours P. Molecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance. Gastroenterology Clinics of North America 2015;44:577-96. [DOI: 10.1016/j.gtc.2015.05.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
133 Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract. 2010;64:1530-1534. [PMID: 20846200 DOI: 10.1111/j.1742-1241.2010.02482.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
134 Tran VH, Ha TMT, Le PTQ, Phan TN, Tran TNH. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin-resistant phenotype in central Vietnam. Journal of Global Antimicrobial Resistance 2019;16:87-91. [DOI: 10.1016/j.jgar.2018.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
135 Steichen M, Decrem Y, Godfroid E, Buess-Herman C. Electrochemical DNA hybridization detection using peptide nucleic acids and [Ru(NH3)6]3+ on gold electrodes. Biosens Bioelectron 2007;22:2237-43. [PMID: 17166712 DOI: 10.1016/j.bios.2006.10.041] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 6.4] [Reference Citation Analysis]
136 Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015;42:131-41. [PMID: 26011564 DOI: 10.1111/apt.13259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
137 Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413-422. [PMID: 20628905 DOI: 10.1007/s00508-010-1404-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
138 Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008;60:409-415. [PMID: 18248937 DOI: 10.1016/j.diagmicrobio.2007.11.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
139 Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
140 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus. World J Gastroenterol 2014;20:10969-83. [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
141 Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. [PMID: 28109257 DOI: 10.1186/s12876-017-0579-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
142 Chung WC, Jung SH, Oh JH, Kim TH, Cheung DY, Kim BW, Kim SS, Kim JI, Sin EY. Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection. World J Gastroenterol. 2014;20:6547-6553. [PMID: 24914376 DOI: 10.3748/wjg.v20.i21.6547] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
143 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-13437. [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
144 Valooran GJ, Kate V, Jagdish S, Basu D. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. Scand J Gastroenterol. 2011;46:1045-1050. [PMID: 21627398 DOI: 10.3109/00365521.2011.584894] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
145 Mouery K, Rader BA, Gaynor EC, Guillemin K. The stringent response is required for Helicobacter pylori survival of stationary phase, exposure to acid, and aerobic shock. J Bacteriol. 2006;188:5494-5500. [PMID: 16855239 DOI: 10.1128/jb.00366-06] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
146 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
147 Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-325. [PMID: 20054285 DOI: 10.1097/mcg.0b013e3181c8a1a3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
148 Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in Helicobacter pylori: A mutational analysis from a tertiary care hospital in Kashmir, India. Indian J Med Microbiol. 2018;36:265-272. [PMID: 30084422 DOI: 10.4103/ijmm.ijmm_18_19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
149 Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother. 2012;56:550-551. [PMID: 22064536 DOI: 10.1128/AAC.05243-11] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
150 Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J, Tumwasorn S. Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter. 2014;19:144-155. [PMID: 24387083 DOI: 10.1111/hel.12105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
151 Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter. 2007;12:364-365. [PMID: 17669111 DOI: 10.1111/j.1523-5378.2007.00517.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
152 Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385-5402. [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
153 Yakoob J, Jafri W, Abbas Z, Abid S, Naz S, Khan R, Khalid A. Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area. Epidemiol Infect 2011;139:581-90. [PMID: 20525411 DOI: 10.1017/S0950268810001226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
154 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15 Suppl 1:46-52. [PMID: 21054653 DOI: 10.1111/j.1523-5378.2010.00774.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
155 Gisbert JP. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterología y Hepatología 2011;34:89-99. [DOI: 10.1016/j.gastrohep.2010.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
156 Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol. 2015;21:11654-11672. [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
157 Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, Akyıldız E, Topbaş M, Özgür O, Arslan M. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol 2020;31:221-33. [PMID: 32343234 DOI: 10.5152/tjg.2020.18631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Kostamo P, Veijola L, Oksanen A, Sarna S, Rautelin H. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. Int J Antimicrob Agents. 2011;37:22-25. [PMID: 21084175 DOI: 10.1016/j.ijantimicag.2010.09.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
159 Ghotaslou R, Milani M, Akhi MT, Hejazi MS, Nahaei MR, Hasani A, Sharifi Y. Relationship Between Drug Resistance and cagA Gene in Helicobacter pylori. Jundishapur J Microbiol 2013;6. [DOI: 10.5812/jjm.8480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
160 Khashei R, Dara M, Bazargani A, Bagheri Lankarani K, Taghavi A, Moeini M, Dehghani B, Sohrabi M. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. APMIS. 2016; Jun. 30 [Epub ahead of print]. [PMID: 27357065 DOI: 10.1111/apm.12567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
161 Vale FF, Vítor JM. Transmission pathway of Helicobacter pylori: does food play a role in rural and urban areas? Int J Food Microbiol. 2010;138:1-12. [PMID: 20122750 DOI: 10.1016/j.ijfoodmicro.2010.01.016] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
162 Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults. Clinical Therapeutics 2010;32:2003-11. [DOI: 10.1016/j.clinthera.2010.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
163 Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
164 Liu W, Liu Y, Zhang XZ, Li N, Cheng H. In vitro bactericidal activity of Jinghua Weikang Capsule and its individual herb Chenopodium ambrosioides L. against antibiotic-resistant Helicobacter pylori. Chin J Integr Med. 2013;19:54-57. [PMID: 23275015 DOI: 10.1007/s11655-012-1248-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
165 De Francesco V, Zullo A, Giorgio F, Saracino I, Zaccaro C, Hassan C, Ierardi E, Di Leo A, Fiorini G, Castelli V. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol. 2014;63:453-457. [PMID: 24344205 DOI: 10.1099/jmm.0.067942-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
166 Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther. 2011;34:1098-1105. [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
167 Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol. 2011;26:825-828. [PMID: 21251064 DOI: 10.1111/j.1440-1746.2011.06660.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
168 Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
169 Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
170 Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715-1720. [PMID: 26338726 DOI: 10.1136/gutjnl-2015-309900] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
171 Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99-108. [DOI: 10.1016/j.cimid.2019.02.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
172 Woo HY, Park DI, Park H, Kim MK, Kim DH, Kim IS, Kim YJ. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter. 2009;14:22-28. [PMID: 19191892 DOI: 10.1111/j.1523-5378.2009.00654.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
173 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
174 Aydemir S, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, Yilmaz U. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol. 2005;11:842-845. [PMID: 15682477 DOI: 10.3748/wjg.v11.i6.842] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
175 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Reference Citation Analysis]
176 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
177 Gisbert JP, Mcnicholl AG. Maintenance of Helicobacter pylori Eradication Rates with Triple Therapy Over 12 Years in a Spanish hospital: Letter to the Editor. Helicobacter 2012;17:160-1. [DOI: 10.1111/j.1523-5378.2011.00922.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
178 Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936-5942. [PMID: 25070099 DOI: 10.1128/aac.02922-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
179 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
180 Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 133] [Article Influence: 19.1] [Reference Citation Analysis]
181 Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21:10644-10653. [PMID: 26457024 DOI: 10.3748/wjg.v21.i37.10644] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
182 De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59:783-785. [PMID: 17329269 DOI: 10.1093/jac/dkm005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
183 Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter. 2007;12:623-628. [PMID: 18001404 DOI: 10.1111/j.1523-5378.2007.00548.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
184 Parreira P, Magalhães A, Gonçalves IC, Gomes J, Vidal R, Reis CA, Leckband DE, Martins MCL. Effect of surface chemistry on bacterial adhesion, viability, and morphology. J Biomed Mater Res 2011;99A:344-53. [DOI: 10.1002/jbm.a.33178] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
185 Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
186 Rezaee P, Kermanshahi RK, Falsafi T. Antibacterial activity of lactobacilli probiotics on clinical strains of Helicobacter pylori. Iran J Basic Med Sci 2019;22:1118-24. [PMID: 31998451 DOI: 10.22038/ijbms.2019.33321.7953] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
187 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
188 Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521-528. [PMID: 17215846 DOI: 10.1038/sj.clpt.6100043] [Cited by in Crossref: 122] [Cited by in F6Publishing: 98] [Article Influence: 8.7] [Reference Citation Analysis]
189 Boyanova L, Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I. High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis 2009;64:374-80. [PMID: 19631090 DOI: 10.1016/j.diagmicrobio.2009.04.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
190 Gisbert JP, Fuentes J, Carpio D, Tito L, Guardiola J, Tomas A, Olivares D, Calvet X. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2005;21:1249-1253. [PMID: 15882246 DOI: 10.1111/j.1365-2036.2005.02465.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
191 Vakil N. Editorial: H. pylori Treatment: New Wine in Old Bottles? Am J Gastroenterol 2009;104:26-30. [DOI: 10.1038/ajg.2008.91] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
192 Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011;55:1123-1129. [PMID: 21189342 DOI: 10.1128/aac.01131-10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
193 Costa S, Soares JB, Gonçalves R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2017;29:1258-63. [PMID: 28877088 DOI: 10.1097/MEG.0000000000000960] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
194 Kim SY, Jung SW. [Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol 2011;58:67-73. [PMID: 21873820 DOI: 10.4166/kjg.2011.58.2.67] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
195 Yue JY, Yue J, Wang MY, Song WC, Gao XZ. CagA status & genetic characterization of metronidazole resistant strains of H. pylori from: A region at high risk of gastric cancer. Pak J Med Sci 2014;30:804-8. [PMID: 25097521 DOI: 10.12669/pjms.304.4840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Cerqueira L, Fernandes RM, Ferreira RM, Carneiro F, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Azevedo NF, Vieira MJ. PNA-FISH as a new diagnostic method for the determination of clarithromycin resistance of Helicobacter pylori. BMC Microbiol. 2011;11:101. [PMID: 21569555 DOI: 10.1186/1471-2180-11-101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
197 Park HK, Lee DH, Suh S, Seo PJ, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM. Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection. Clin Endosc 2011;44:33-7. [PMID: 22741110 DOI: 10.5946/ce.2011.44.1.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
198 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 256] [Article Influence: 51.7] [Reference Citation Analysis]
199 Barile KA, Silva AL, Xavier JN, Assumpção MB, Corvelo TC. Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon. Mem Inst Oswaldo Cruz 2010;105:314-7. [PMID: 20512246 DOI: 10.1590/s0074-02762010000300012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
200 Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, Fadgyas-Freyler P, Szénás K, Rugge M, Fassan M, Kiss A, Schaff Z, Röst G, Lotz G. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun 2021;12:2255. [PMID: 33859206 DOI: 10.1038/s41467-021-22557-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
201 Sanches B, Coelho L, Moretzsohn L, Vieira G. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13:572-576. [PMID: 19166424 DOI: 10.1111/j.1523-5378.2008.00649.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
202 Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420-426. [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
203 Alfizah H, Norazah A, Hamizah R, Ramelah M. Resistotype of Helicobacter pylori isolates: the impact on eradication outcome. J Med Microbiol. 2014;63:703-709. [PMID: 24757218 DOI: 10.1099/jmm.0.069781-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
204 Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006;12:2313-9. [PMID: 16688818 DOI: 10.3748/wjg.v12.i15.2313] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
205 Kuo CH, Liu CJ, Yang CC, Kuo FC, Hu HM, Shih HY, Wu MC, Chen YH, Wang HM, Ren JL. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. Medicine (Baltimore). 2016;95:e3458. [PMID: 27227911 DOI: 10.1097/md.0000000000003458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
206 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
207 Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21:315-324. [PMID: 17382279 DOI: 10.1016/j.bpg.2006.11.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
208 O'connor A, Gisbert J, O’morain C. Treatment of Helicobacter pylori Infection. Helicobacter 2009;14:46-51. [DOI: 10.1111/j.1523-5378.2009.00704.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
209 Furuta T, Soya Y, Sugimoto M, Shirai N, Nakamura A, Kodaira C, Nishino M, Okuda M, Okimoto T, Murakami K, Fujioka T, Hishida A. Modified allele-specific primer–polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol 2007;22:1810-5. [DOI: 10.1111/j.1440-1746.2007.04919.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
210 Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm. 2012;9:2677-2685. [PMID: 22827534 DOI: 10.1021/mp300243w] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
211 Coelho LGV. Rescue therapy with levofloxacin after multiple H. pylori treatment failures: Author's reply. Aliment Pharmacol Ther 2005;22:654-5. [DOI: 10.1111/j.1365-2036.2005.02640.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
212 Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507-514. [PMID: 21777974 DOI: 10.1016/s0140-6736(11)60825-8] [Cited by in Crossref: 171] [Cited by in F6Publishing: 75] [Article Influence: 17.1] [Reference Citation Analysis]
213 Allison R, Lecky DM, Bull M, Turner K, Godbole G, McNulty CA. Audit of Helicobacter pylori Testing in Microbiology Laboratories in England: To Inform Compliance with NICE Guidance and the Feasibility of Routine Antimicrobial Resistance Surveillance. Int J Microbiol 2016;2016:8540904. [PMID: 27829836 DOI: 10.1155/2016/8540904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
214 Maleknejad S, Mojtahedi A, Safaei-Asl A, Taghavi Z, Kazemnejad E. Primary Antibiotic Resistance to Helicobacter pylori Strains Isolated From Children in Northern Iran: A Single Center Study. Iran J Pediatr. 2015;25:e2661. [PMID: 26635938 DOI: 10.5812/ijp.2661] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
215 Mamori S, Higashida A, Kawara F, Ohnishi K, Takeda A, Senda E, Ashida C, Yamada H. Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol 2010;16:4176-9. [PMID: 20806435 DOI: 10.3748/wjg.v16.i33.4176] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
216 Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010;8:59-70. [PMID: 20014902 DOI: 10.1586/eri.09.113] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
217 Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol. 2016;22:7587-7594. [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
218 Naserpour Farivar T, Najafipour R, Johari P. Prevalence of clarithromycin-resistant Helicobacter pylori in patients with chronic tonsillitis by allele-specific scorpion real-time polymerase chain reaction assay: Clarithromycin-Resistant H. pylori. The Laryngoscope 2013;123:1478-82. [DOI: 10.1002/lary.23777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
219 Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter. 2007;12:68-73. [PMID: 17241304 DOI: 10.1111/j.1523-5378.2007.00472.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
220 Juvale K, Purushothaman G, Singh V, Shaik A, Ravi S, Thiruvenkatam V, Kirubakaran S. Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection. Sci Rep 2019;9:190. [PMID: 30655593 DOI: 10.1038/s41598-018-37490-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
221 Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31:227-238. [PMID: 21361732 DOI: 10.1592/phco.31.3.227] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
222 Lee JW, Kim N, Nam RH, Park JH, Choi YJ, Kim JM, Kim JS, Jung HC. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scand J Gastroenterol. 2014;49:1058-1067. [PMID: 24957849 DOI: 10.3109/00365521.2014.894117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
223 Malfertheiner P, Bazzoli F, Delchier J, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011;377:905-13. [DOI: 10.1016/s0140-6736(11)60020-2] [Cited by in Crossref: 310] [Cited by in F6Publishing: 103] [Article Influence: 31.0] [Reference Citation Analysis]
224 De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther. 2012;3:68-73. [PMID: 22966485 DOI: 10.4292/wjgpt.v3.i4.68] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
225 . Late breaking abstracts. United European Gastroenterol j 2018;6:1586-97. [DOI: 10.1177/2050640618812015] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Kalkan IH, Sapmaz F, Güliter S, Atasoy P. Severe gastritis decreases success rate of Helicobacter pylori eradication. Wien Klin Wochenschr 2016;128:329-34. [PMID: 26637331 DOI: 10.1007/s00508-015-0896-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
227 Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: Where are we now? J Gastroenterol Hepatol. 2016;31:1918-1926. [PMID: 27088632 DOI: 10.1111/jgh.13418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
228 Tonkic A, Tonkic M, Brnic D, Novak A, Puljiz Z, Simunic M. Time trends of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia. Journal of Chemotherapy 2013;24:182-4. [DOI: 10.1179/1973947812y.0000000001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
229 Hashemi SJ, Sheikh AF, Goodarzi H, Yadyad MJ, Seyedian SS, Aslani S, Assarzadegan MA. Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders. Infect Drug Resist. 2019;12:535-543. [PMID: 30881059 DOI: 10.2147/idr.s192942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
230 Gong YN, Li YM, Yang NM, Li HZ, Guo F, Lin L, Wang QY, Zhang JK, Ji ZZ, Mao JB. Centralized isolation of Helicobacter pylori from multiple centers and transport condition influences. World J Gastroenterol. 2015;21:944-952. [PMID: 25624729 DOI: 10.3748/wjg.v21.i3.944] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
231 Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol. 2013;37:642-646. [PMID: 23796974 DOI: 10.1016/j.clinre.2013.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
232 Tsay FW, Wu DC, Kao SS, Tsai TJ, Lai KH, Cheng JS, Chan HH, Wang HM, Tsai WL, Tseng HH, Peng NJ, Hsu PI. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter 2015;20:71-7. [PMID: 25495272 DOI: 10.1111/hel.12176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
233 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Reference Citation Analysis]
234 Medeiros JA, Gonçalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011;30:555-559. [PMID: 21207091 DOI: 10.1007/s10096-010-1119-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
235 Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE, Megraud F, Douidi KT. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. Journal of Antimicrobial Chemotherapy 2018;73:2034-8. [DOI: 10.1093/jac/dky167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
236 Cerqueira L, Fernandes RM, Ferreira RM, Oleastro M, Carneiro F, Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Vieira MJ, Azevedo NF. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013;51:1887-93. [PMID: 23596234 DOI: 10.1128/JCM.00302-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
237 Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47:233-238. [PMID: 23090037 DOI: 10.1097/mcg.0b013e3182676e2b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
238 Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930-935. [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
239 Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK. A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial. Infect Drug Resist 2019;12:2923-31. [PMID: 31571945 DOI: 10.2147/IDR.S213998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
241 Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005;22:1041-6. [DOI: 10.1111/j.1365-2036.2005.02687.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
242 Tankovic J, Chaumette-planckaert M, Deforges L, Launay N, Le Glaunec J, Soussy C, Delchier J. Routine use of real-time PCR for detection of Helicobacter pylori and of clarithromycin resistance mutations. Gastroentérologie Clinique et Biologique 2007;31:792-5. [DOI: 10.1016/s0399-8320(07)73967-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
243 Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol. 2009;25:549-556. [PMID: 19696666 DOI: 10.1097/mog.0b013e32833159f2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
244 Ghobadi E, Ghanbarimasir Z, Emami S. A review on the structures and biological activities of anti-Helicobacter pylori agents. Eur J Med Chem 2021;223:113669. [PMID: 34218084 DOI: 10.1016/j.ejmech.2021.113669] [Reference Citation Analysis]
245 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
246 Yang Y, Ouyang R, Xu L, Guo N, Li W, Feng K, Ouyang L, Yang Z, Zhou S, Miao Y. Review: Bismuth complexes: synthesis and applications in biomedicine. Journal of Coordination Chemistry 2015;68:379-97. [DOI: 10.1080/00958972.2014.999672] [Cited by in Crossref: 70] [Cited by in F6Publishing: 21] [Article Influence: 11.7] [Reference Citation Analysis]
247 Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24:139-149. [PMID: 29358890 DOI: 10.3748/wjg.v24.i1.139] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
248 Quiding-Järbrink M, Bove M, Dahlén G. Infections of the esophagus and the stomach. Periodontol 2000 2009;49:166-78. [PMID: 19152533 DOI: 10.1111/j.1600-0757.2008.00280.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
249 Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012;36:1076-1083. [PMID: 23072648 DOI: 10.1111/apt.12089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
250 Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124:157-166. [PMID: 18823009 DOI: 10.1002/ijc.23864] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
251 Hamada M, Elbehiry A, Marzouk E, Moussa IM, Hessain AM, Alhaji JH, Heme HA, Zahran R, Abdeen E. Helicobacter pylori in a poultry slaughterhouse: Prevalence, genotyping and antibiotic resistance pattern. Saudi J Biol Sci 2018;25:1072-8. [PMID: 30174504 DOI: 10.1016/j.sjbs.2018.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90. [PMID: 21655065 DOI: 10.3346/jkms.2011.26.6.785] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
253 Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015;13:1616-1624. [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 15.5] [Reference Citation Analysis]
254 Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol. 2014;20:5252-5262. [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
255 Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-548. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
256 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
257 Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter pylori : past, current and future treatment strategies with gastroretentive drug delivery systems. Journal of Drug Targeting 2016;24:897-915. [DOI: 10.3109/1061186x.2016.1171326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
258 Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol. 2013;19:5508-5512. [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
259 Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 6.1] [Reference Citation Analysis]
260 Kasiri KA, Khoshdel A, Karimi A, Sedehi M, Kasiri N. Comparison of amoxicillin and metronidazole effect on three-drug regimen for the treatment of Helicobacter pylori infection in children. J Adv Pharm Technol Res. 2017;8:63-66. [PMID: 28516058 DOI: 10.4103/japtr.japtr_162_16] [Reference Citation Analysis]
261 Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
262 Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother. 2013;68:1562-1566. [PMID: 23463210 DOI: 10.1093/jac/dkt061] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
263 Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol 2013;4:e32. [PMID: 23535826 DOI: 10.1038/ctg.2013.3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
264 Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16:2307-2317. [PMID: 26330278 DOI: 10.1517/14656566.2015.1084503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
265 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
266 Kwack W, Lim Y, Lim C, Graham DY. High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea. Gastroenterol Res Pract 2016;2016:1648047. [PMID: 27413365 DOI: 10.1155/2016/1648047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
267 Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, Bory F, Barenys M, Bujanda L, Lisozain J, Calvo MM, Torra S, Gisbert JP. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2012;36:190-196. [PMID: 22591220 DOI: 10.1111/j.1365-2036.2012.05137.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
268 Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014;45:1439-48. [PMID: 25763052 DOI: 10.1590/s1517-83822014000400039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
269 Biernat MM, Poniewierka E, Błaszczuk J, Czapla L, Kempiński R, Ksiądzyna D, Grabińska J, Bińkowska A, Megraud F, Gościniak G. Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland. Arch Med Sci 2014;10:505-9. [PMID: 25097581 DOI: 10.5114/aoms.2013.36917] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
270 Kwok A, Lam T, Katelaris P, Leong RW. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7:271-81. [PMID: 18462185 DOI: 10.1517/14740338.7.3.271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
271 Haghdoost M, Taghizadeh S, Montazer M, Poorshahverdi P, Ramouz A, Fakour S. Double strain probiotic effect on Helicobacter pylori infection treatment: A double-blinded randomized controlled trial. Caspian J Intern Med 2017;8:165-71. [PMID: 28932367 DOI: 10.22088/cjim.8.3.165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 11.5] [Reference Citation Analysis]
273 Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter. 2009;14:29-35. [PMID: 19191893 DOI: 10.1111/j.1523-5378.2009.00656.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
274 Gisbert JP, Bermejo MF, Infante JM, Gallardo BP, Bermejo AB, Rodríguez JM, Andrés PR, García GG. Levofloxacin, Amoxicillin, and Omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2009;43:384-385. [PMID: 19020466 DOI: 10.1097/mcg.0b013e31816d921c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
275 Bińkowska A, Biernat MM, Łaczmański Ł, Gościniak G. Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland. Front Microbiol 2018;9:3154. [PMID: 30619218 DOI: 10.3389/fmicb.2018.03154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
276 Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019;25:1907-12. [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
277 Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol 2020;55:969-76. [DOI: 10.1007/s00535-020-01709-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
278 Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012;67:2254-2259. [PMID: 22687889 DOI: 10.1093/jac/dks209] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
279 Wong F, Ou G, Svarta S, Kwok R, Donaldson K, Frenette J, Enns R. Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease? Can J Gastroenterol 2013;27:636-8. [PMID: 24040632 DOI: 10.1155/2013/249562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
280 Kwon JH, Lee DH, Song BJ, Lee JW, Kim JJ, Park YS, Kim N, Jeong SH, Kim JW, Lee SH. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter. 2010;15:148-153. [PMID: 20402817 DOI: 10.1111/j.1523-5378.2010.00748.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
281 De Francesco V, Margiotta M, Zullo A, Hassan C, Valle ND, Burattini O, Cea U, Stoppino G, Amoruso A, Stella F. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther. 2006;23:429-435. [PMID: 16423002 DOI: 10.1111/j.1365-2036.2006.02769.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
282 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34:700-706. [PMID: 30011083 DOI: 10.1111/jgh.14383] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
283 Mégraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs. 2004;64:1893-1904. [PMID: 15329036 DOI: 10.2165/00003495-200464170-00003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
284 Eng NF, Ybazeta G, Chapman K, Fraleigh NL, Letto R, Altman E, Diaz-Mitoma F. Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario. Can J Infect Dis Med Microbiol 2015;26:137-44. [PMID: 26236355 DOI: 10.1155/2015/853287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
285 Chen M, Wu M, Chen C, Chen C, Fang Y, Bair M, Chang C, Lee J, Hsu W, Luo J, Lin J, Liou J; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. Journal of Antimicrobial Chemotherapy 2017;72:3481-9. [DOI: 10.1093/jac/dkx320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
286 Cho DK, Park SY, Kee WJ, Lee JH, Ki HS, Yoon KW, Cho SB, Lee WS, Joo YE, Kim HS, Choi SK, Rew JS. [The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy]. Korean J Gastroenterol 2010;55:368-75. [PMID: 20571304 DOI: 10.4166/kjg.2010.55.6.368] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
287 Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645-648. [PMID: 23403439 DOI: 10.1097/mpg.0b013e31828b3669] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
288 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828] [Reference Citation Analysis]
289 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
290 Yang YH, Wu WK, Tai EK, Wong HP, Lam EK, So WH, Shin VY, Cho CH. The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats. J Pharmacol Exp Ther. 2006;318:547-554. [PMID: 16670350 DOI: 10.1124/jpet.106.102467] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
291 Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131-138. [PMID: 21435091 DOI: 10.1111/j.1523-5378.2011.00826.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
292 Thamphiwatana S, Gao W, Obonyo M, Zhang L. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A. 2014;111:17600-17605. [PMID: 25422427 DOI: 10.1073/pnas.1418230111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
293 Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bästlein E, Jacobs E, Bayerdörffer E. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24:395-403. [PMID: 16842467 DOI: 10.1111/j.1365-2036.2006.02993.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
294 Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS. 2013;121:353-358. [PMID: 23083455 DOI: 10.1111/apm.12009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
295 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
296 Ubhayawardana NL, Weerasekera MM, Weerasekera D, Samarasinghe K, Gunasekera CP, Fernando N. Detection of clarithromycin-resistant Helicobacter pylori strains in a dyspeptic patient population in Sri Lanka by polymerase chain reaction-restriction fragment length polymorphism. Indian J Med Microbiol 2015;33:374-7. [PMID: 26068338 DOI: 10.4103/0255-0857.158557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
297 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol. 2014;20:665-672. [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
298 Bhattamisra SK, Kuean CH, Chieh LB, Yan VLY, Lee CK, Hooi LP, Shyan LP, Liew YK, Candasamy M, Sahu PS. Antibacterial Activity of Geraniol in Combination with Standard Antibiotics against Staphylococcus aureus, Escherichia coli and Helicobacter pylori. Natural Product Communications 2018;13:1934578X1801300. [DOI: 10.1177/1934578x1801300701] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
299 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. [PMID: 17170018 DOI: 10.1136/gut.2006.101634.] [Reference Citation Analysis]
300 O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14:230-240. [PMID: 28053340 DOI: 10.1038/nrgastro.2016.195] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 19.3] [Reference Citation Analysis]
301 Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 2009;47:3600-3607. [PMID: 19759218 DOI: 10.1128/jcm.00744-09] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
302 Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol. 2006;40:515-520. [PMID: 16825934 DOI: 10.1097/00004836-200607000-00010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
303 Aboderin OA, Abdu AR, Odetoyin B’, Okeke IN, Lawal OO, Ndububa DA, Agbakwuru AE, Lamikanra A. Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci. 2007;7:143-147. [PMID: 18052867 DOI: 10.5555/afhs.2007.7.3.143] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
304 Zheng HL, Hu YM, Bao JJ, Xu JM. Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole. Acta Pharmacol Sin 2010;31:501-8. [PMID: 20305682 DOI: 10.1038/aps.2009.191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
305 Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008;13:69-74. [PMID: 18205669 DOI: 10.1111/j.1523-5378.2007.00588.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
306 De Francesco V, Zullo A, Perna F, Giorgio F, Hassan C, Vannella L, Cristofari F, Panella C, Vaira D, Ierardi E. Helicobacter pylori antibiotic resistance and [13C]urea breath test values. J Med Microbiol. 2010;59:588-591. [PMID: 20093375 DOI: 10.1099/jmm.0.018077-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
307 Zullo A, De Francesco V, Scaccianoce G, Manes G, Efrati C, Hassan C, Maconi G, Piglionica D, Cannaviello C, Panella C. Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. Dig Liver Dis. 2007;39:806-810. [PMID: 17644057 DOI: 10.1016/j.dld.2007.05.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
308 Yang JC, Shun CT, Chien CT, Wang TH. Effective prevention and treatment of Helicobacter pylori infection using a combination of catechins and sialic acid in AGS cells and BALB/c mice. J Nutr. 2008;138:2084-2090. [PMID: 18936202 DOI: 10.3945/jn.108.090985] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
309 Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, Das R. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J Glob Antimicrob Resist. 2016;6:39-43. [PMID: 27530837 DOI: 10.1016/j.jgar.2016.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
310 Fuccio L, Zagari RM, Bazzoli F. What is the best salvage therapy for patients with Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol 2008;5:608-9. [PMID: 18797442 DOI: 10.1038/ncpgasthep1256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
311 Tonkić A, Tonkić M, Brnić D. Increasing Prevalence of Primary Clarithromycin Resistance in Helicobacter pylori Strains in Split, Croatia. Journal of Chemotherapy 2013;21:598-9. [DOI: 10.1179/joc.2009.21.5.598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
312 Choi J, Jang JY, Kim JS, Park HY, Choe YH, Kim KM. Efficacy of two triple eradication regimens in children with Helicobacter pylori infection. J Korean Med Sci 2006;21:1037-40. [PMID: 17179683 DOI: 10.3346/jkms.2006.21.6.1037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
313 Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014;20:9898-911. [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
315 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
316 Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380-1384. [PMID: 25229983 DOI: 10.1097/meg.0000000000000197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
317 Burucoa C, Garnier M, Silvain C, Fauchère JL. Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol. 2008;46:2320-2326. [PMID: 18463216 DOI: 10.1128/jcm.02352-07] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
318 Treiber G, Malfertheiner P, Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007;8:329-50. [PMID: 17266468 DOI: 10.1517/14656566.8.3.329] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
319 Seia MA, Pereira SV, Fontán CA, De Vito IE, Messina GA, Raba J. Laser-induced fluorescence integrated in a microfluidic immunosensor for quantification of human serum IgG antibodies to Helicobacter pylori. Sensors and Actuators B: Chemical 2012;168:297-302. [DOI: 10.1016/j.snb.2012.04.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
320 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
321 Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2012;35:1097-1102. [PMID: 22404486 DOI: 10.1111/j.1365-2036.2012.05054.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
322 Karczewska E, Wojtas-Bonior I, Sito E, Zwolińska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011;63:799-807. [PMID: 21857091 DOI: 10.1016/s1734-1140(11)70592-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
323 Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? Pharmacogn Rev 2017;11:57-72. [PMID: 28989242 DOI: 10.4103/phrev.phrev_21_17] [Cited by in Crossref: 150] [Cited by in F6Publishing: 88] [Article Influence: 37.5] [Reference Citation Analysis]
324 Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
325 Calvino-Fernández M, García-Fresnadillo D, Benito-Martínez S, McNicholl AG, Calvet X, Gisbert JP, Parra-Cid T. Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Med Chem. 2013;68:284-290. [PMID: 23988411 DOI: 10.1016/j.ejmech.2013.07.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
326 Mishra S, Singh V, Rao GR, Dixit VK, Gulati AK, Nath G. Prevalence of Helicobacter pylori in asymptomatic subjects--a nested PCR based study. Infect Genet Evol. 2008;8:815-819. [PMID: 18771754 DOI: 10.1016/j.meegid.2008.08.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
327 Molina-infante J, Pazos-pacheco C, Vinagre-rodriguez G, Perez-gallardo B, Dueñas-sadornil C, Hernandez-alonso M, Gonzalez-garcia G, Mateos-rodriguez JM, Fernandez-bermejo M, Gisbert JP. Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains: Nonbismuth Quadruple Concomitant Therapy for Helicobacter pylori infection. Helicobacter 2012;17:269-76. [DOI: 10.1111/j.1523-5378.2012.00947.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
328 Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-1235. [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
329 Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009;104:1932-197; quiz 1938. [PMID: 19532131 DOI: 10.1038/ajg.2009.314] [Cited by in Crossref: 55] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
330 Makobongo MO, Einck L, Peek RM Jr, Merrell DS. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One. 2013;8:e68917. [PMID: 23935905 DOI: 10.1371/journal.pone.0068917] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
331 Seo J, Jun J, Yeom JS, Park JS, Youn H, Ko G, Baik S, Lee W, Cho M, Rhee K. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea: H. pylori and antibiotic resistance. Pediatr Int 2013;55:332-6. [DOI: 10.1111/ped.12048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
332 Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724. [PMID: 30768161 DOI: 10.1093/jac/dkz046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 29.0] [Reference Citation Analysis]
333 Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol. 2013;19:8168-8180. [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
334 Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol. 2006;40:683-687. [PMID: 16940878 DOI: 10.1097/00004836-200609000-00004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 5.5] [Reference Citation Analysis]
335 Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now! Therap Adv Gastroenterol. 2009;2:317-322. [PMID: 21180579 DOI: 10.1177/1756283x09343326] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
336 Gong EJ, Ahn JY, Kim JM, Lee SM, Na HK, Lee JH, Jung KW, Choi KD, Kim DH, Song HJ, Lee GH, Kim SW, Jung HY. Genotypic and Phenotypic Resistance to Clarithromycin in Helicobacter pylori Strains. J Clin Med 2020;9:E1930. [PMID: 32575584 DOI: 10.3390/jcm9061930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
337 Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obes Surg 2018;28:743-7. [PMID: 29076008 DOI: 10.1007/s11695-017-2915-z] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
338 Qureshi NN, Morikis D, Schiller NL. Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother. 2011;55:101-109. [PMID: 20956585 DOI: 10.1128/AAC.00545-10] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
339 Cai W, Zhou L, Ren W, Deng L, Yu M. Variables influencing outcome of Helicobacter pylori eradication therapy in South China. Helicobacter. 2009;14:91-96. [PMID: 19751433 DOI: 10.1111/j.1523-5378.2009.00718.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
340 Kim JY, Kim N, Park HK, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH. [Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea]. Korean J Gastroenterol. 2011;58:74-81. [PMID: 21873821 DOI: 10.4166/kjg.2011.58.2.74] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
341 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011;17:3971-3975. [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 91] [Article Influence: 10.8] [Reference Citation Analysis]
342 Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
343 Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis. 2010;42:541-543. [PMID: 20061196 DOI: 10.1016/j.dld.2009.12.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
344 Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter. 2006;11:243-249. [PMID: 16882327 DOI: 10.1111/j.1523-5378.2006.00415.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 5.6] [Reference Citation Analysis]
345 Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract 2016;2016:9086581. [PMID: 28070184 DOI: 10.1155/2016/9086581] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
346 Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A, Elouennas M, Benouda A. Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study. Microb Drug Resist. 2017;23:727-732. [PMID: 27996373 DOI: 10.1089/mdr.2016.0264] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
347 Gisbert JP, Castro-Fernández M, Bermejo F, Pérez-Aisa A, Ducons J, Fernández-Bermejo M, Bory F, Cosme A, Benito LM, López-Rivas L. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101:243-247. [PMID: 16454825 DOI: 10.1111/j.1572-0241.2006.00457.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
348 Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J Med Microbiol. 2012;61:85-93. [PMID: 21873378 DOI: 10.1099/jmm.0.035568-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
349 Peng X, Song Z, He L, Lin S, Gong Y, Sun L, Zhao F, Gu Y, You Y, Zhou L, Zhang J. Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach. Int J Med Sci. 2017;14:595-601. [PMID: 28638276 DOI: 10.7150/ijms.18996] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
350 Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol. 2015;21:5032-5038. [PMID: 25945019 DOI: 10.3748/wjg.v21.i16.5032] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
351 González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, Miranda-Cordero RM, Hinojosa-Ruiz A, Mejía-García E, Cruz-González EG. [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym]. Rev Gastroenterol Mex. 2012;77:114-118. [PMID: 22921101 DOI: 10.1016/j.rgmx.2012.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
352 Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, Panteleeva E, Spassova Z, Mitov I. Two-decade trends in primary Helicobacter pylori resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010;67:319-326. [PMID: 20638598 DOI: 10.1016/j.diagmicrobio.2010.03.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
353 Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC; Taiwan Acid-Related Disease (TARD) Study Group. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter. 2014;19:74-79. [PMID: 24033865 DOI: 10.1111/hel.12085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
354 Yahaghi E, Khamesipour F, Mashayekhi F, Safarpoor Dehkordi F, Sakhaei MH, Masoudimanesh M, Khameneie MK. Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties. Biomed Res Int 2014;2014:757941. [PMID: 25184146 DOI: 10.1155/2014/757941] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
355 Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
356 Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H pylori eradication in Iran. World J Gastroenterol. 2006;12:4553-4556. [PMID: 16874871 DOI: 10.3748/wjg.v12.i28.4553] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
357 Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
358 Touati E, Michel V, Correia M, Menghini L, Genovese S, Curini M, Epifano F. Boropinic acid, a novel inhibitor of Helicobacter pylori stomach colonization. Journal of Antimicrobial Chemotherapy 2009;64:210-1. [DOI: 10.1093/jac/dkp136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
359 Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008;14:6065-71. [PMID: 18932287 DOI: 10.3748/wjg.14.6065] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
360 Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 35] [Article Influence: 24.0] [Reference Citation Analysis]
361 Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
362 Losurdo G, Giorgio F, Pricci M, Girardi B, Russo F, Riezzo G, Martulli M, Piazzolla M, Cocomazzi F, Abbruzzi F, Parente E, Paolillo R, Mileti A, Iannone A, Principi M, Ierardi E, Leo AD. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics (Basel) 2020;9:E723. [PMID: 33096925 DOI: 10.3390/antibiotics9100723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
363 P. Gisbert J, Calvet X, Gomollón F, Monés J. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso. Medicina Clínica 2005;125:301-16. [DOI: 10.1157/13078424] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
364 Bago J, Majstorović K, Belosić-Halle Z, Kućisec N, Bakula V, Tomić M, Bago P, Troskot R. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob 2010;9:13. [PMID: 20398300 DOI: 10.1186/1476-0711-9-13] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
365 Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56:475-479. [PMID: 17028126 DOI: 10.1136/gut.2006.102269] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
366 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
367 Lee M, Chung JY, Kim KY, Im W, Kim M. Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model. BMC Microbiol 2020;20:372. [PMID: 33297964 DOI: 10.1186/s12866-020-02055-4] [Reference Citation Analysis]
368 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World J Gastroenterol. 2014;20:5654-5659. [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
369 Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
370 Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol 2017;40:658-62. [PMID: 28780968 DOI: 10.1016/j.gastrohep.2017.05.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
371 Xuan S, Zhou Y, Shao B, Cui Y, Li J, Yin H, Song X, Cong H, Jing F, Jin Q, Wang H, Zhou J. Enzymic colorimetry-based DNA chip: a rapid and accurate assay for detecting mutations for clarithromycin resistance in the 23S rRNA gene of Helicobacter pylori. Journal of Medical Microbiology 2009;58:1443-8. [DOI: 10.1099/jmm.0.010785-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
372 Tonkić M, Tonkić A, Goić-barišić I, Šcimunić M, Punda-polić V; Jukić. Primary Resistance and Antibiotic Minimum Inhibitory Concentrations for Helicobacter pylori Strains in Split, Croatia. Journal of Chemotherapy 2013;18:437-9. [DOI: 10.1179/joc.2006.18.4.437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
373 Matsushima M, Takagi A. "Is it effective?" to "How to use it?": the era has changed in probiotics and functional food products against Helicobacter pylori infection. J Gastroenterol Hepatol. 2012;27:851-853. [PMID: 22515805 DOI: 10.1111/j.1440-1746.2012.07094.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
374 Dolapcioglu C, Sayiner M, Akkus EE, Kural A, Dolapcioglu H, Dabak R, Ahishali E. First-line Bismuth-containing Five-day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication. Helicobacter 2016;21:100-5. [PMID: 26103789 DOI: 10.1111/hel.12241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
375 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013;47:130-135. [PMID: 22647827 DOI: 10.1097/mcg.0b013e318254ebdd] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
377 Yilmaz O, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H. pylori infection and determination of clarithromycin resistance in H. pylori eradication therapy. World J Gastroenterol. 2007;13:671-675. [PMID: 17278188 DOI: 10.3748/wjg.v13.i5.671] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
378 Demiray-Gürbüz E, Yılmaz Ö, Olivares AZ, Gönen C, Sarıoğlu S, Soytürk M, Tümer S, Altungöz O, Şimşek İ, Perez Perez GI. Rapid identification of Helicobacter pylori and assessment of clarithromycin susceptibility from clinical specimens using FISH. J Pathol Clin Res 2017;3:29-37. [PMID: 28138399 DOI: 10.1002/cjp2.57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
379 Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354. [PMID: 17999716 DOI: 10.1111/j.1365-2036.2007.03573.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
380 Gisbert JP. Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol. 2011;8:307-309. [PMID: 21643037 DOI: 10.1038/nrgastro.2011.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
381 Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Boyanova L. Detection of Helicobacter pylori infection in symptomatic Bulgarian adults. Clinical Microbiology and Infection 2007;13:908-14. [DOI: 10.1111/j.1469-0691.2007.01770.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
383 Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Association of iceA and babA genotypes in Helicobacter pylori strains with patient and strain characteristics. Antonie Van Leeuwenhoek. 2010;98:343-350. [PMID: 20454856 DOI: 10.1007/s10482-010-9448-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
384 Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis 2017;18:537-42. [PMID: 28644575 DOI: 10.1111/1751-2980.12498] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
385 Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 DOI: 10.3389/pore.2021.1609863] [Reference Citation Analysis]
386 Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol 2005;11:6009-13. [PMID: 16273615 DOI: 10.3748/wjg.v11.i38.6009] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
387 Hanafiah A, Binmaeil H, Raja Ali RA, Mohamed Rose I, Lopes BS. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia. Infect Drug Resist. 2019;12:3051-3061. [PMID: 31632095 DOI: 10.2147/idr.s219069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
388 O'Connor JP, Taneike I, O'Morain C. Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2:273-279. [PMID: 21180555 DOI: 10.1177/1756283x09337342] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
389 Yahav J, Samra Z, Niv Y, Evans CT, Passaro DJ, Dinari G, Shmuely H. Susceptibility-Guided vs. Empiric Retreatment of Helicobacter pylori Infection After Treatment Failure. Dig Dis Sci 2006;51:2316-21. [DOI: 10.1007/s10620-006-9302-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
390 Mousavi S, Dehkordi FS, Rahimi E. Virulence factors and antibiotic resistance of Helicobacter pylori isolated from raw milk and unpasteurized dairy products in Iran. J Venom Anim Toxins Incl Trop Dis. 2014;20:51. [PMID: 25873940 DOI: 10.1186/1678-9199-20-51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
391 De Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer: REVIEW: H. PYLORI ERADICATION FOR GASTRIC CANCER PREVENTION. Alimentary Pharmacology & Therapeutics 2007;26:25-35. [DOI: 10.1111/j.1365-2036.2007.03475.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
392 Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015;21:12954-12962. [PMID: 26668516 DOI: 10.3748/wjg.v21.i45.12954] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
393 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014;20:14973-14985. [PMID: 25356059 DOI: 10.3748/wjg.v20.i40.14973] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
394 Zhang HX, Qiu YY, Zhao YH, Liu XT, Liu M, Yu AL. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes. 2014;28:25-30. [PMID: 24036137 DOI: 10.1016/j.mcp.2013.08.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
395 Kao CY, Lee AY, Huang AH, Song PY, Yang YJ, Sheu SM, Chang WL, Sheu BS, Wu JJ. Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment. Infect Genet Evol. 2014;23:196-202. [PMID: 24576534 DOI: 10.1016/j.meegid.2014.02.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
396 Lewis ND, Asim M, Barry DP, de Sablet T, Singh K, Piazuelo MB, Gobert AP, Chaturvedi R, Wilson KT. Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J Immunol. 2011;186:3632-3641. [PMID: 21296975 DOI: 10.4049/jimmunol.1003431] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
397 Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009;121:47-52. [PMID: 19263014 DOI: 10.1007/s00508-008-1122-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
398 Lim JH, Kim SG, Song JH, Hwang JJ, Lee DH, Han JP, Hong SJ, Kim JH, Jeon SW, Kim GH, Shim KN, Shin WG, Kim TH, Kim SM, Chung IK, Kim HS, Kim HU, Lee J, Kim JG. Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut Liver 2017;11:226-31. [PMID: 27609487 DOI: 10.5009/gnl16099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
399 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22:e12429. [DOI: 10.1111/hel.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
400 Tanih NF, Dube C, Green E, Mkwetshana N, Clarke AM, Ndip LM, Ndip RN. An African perspective on Helicobacter pylori: Prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann Trop Med Parasitol. 2009;103:189-204. [PMID: 19341534 DOI: 10.1179/136485909x398311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
401 Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Terapevticheskii arkhiv 2017;89:5-12. [DOI: 10.17116/terarkh20178985-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
402 Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-1474. [PMID: 17032282 DOI: 10.1111/j.1365-2036.2006.03149.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
403 Modlin I, Sachs G, Wright N, Kidd M. Edkins and a Century of Acid Suppression. Digestion 2005;72:129-45. [DOI: 10.1159/000088368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
404 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93. [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
405 Phan TN, Santona A, Tran VH, Tran TN, Le VA, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents. 2015;45:244-248. [PMID: 25499186 DOI: 10.1016/j.ijantimicag.2014.10.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
406 Yu C, Li L, Chen W, Jiao Y, Yang N, Yang E, Zhang J, Chen L, Li Y. Levofloxacin susceptibility testing for Helicobacter pylori in China: comparison of E-test and disk diffusion method. Helicobacter. 2011;16:119-123. [PMID: 21435089 DOI: 10.1111/j.1523-5378.2011.00820.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
407 Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604-617. [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 103] [Article Influence: 11.6] [Reference Citation Analysis]
408 Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, Aslani MM, Zali MR. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol. 2011;17:261-264. [PMID: 21727733 DOI: 10.4103/1319-3767.82581] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
409 Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, Ierardi E, Cavallo L, Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24:1461-1468. [PMID: 17032283 DOI: 10.1111/j.1365-2036.2006.03145.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 81] [Article Influence: 7.0] [Reference Citation Analysis]
410 Abdollahi H, Savari M, Zahedi MJ, Moghadam SD, Hayatbakhsh Abasi M. Detection of A2142C, A2142G, and A2143G Mutations in 23s rRNA Gene Conferring Resistance to Clarithromycin among Helicobacter pylori Isolates in Kerman, Iran. Iran J Med Sci. 2011;36:104-110. [PMID: 23359224 DOI: 10.1002/dta.162] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
411 Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 90] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
412 Jakobsson H, Wreiber K, Fall K, Fjelstad B, Nyrén O, Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis 2007;39:757-63. [PMID: 17701712 DOI: 10.1080/00365540701299608] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
413 Binh TT, Suzuki R, Shiota S, Kwon DH, Yamaoka Y. Complete Genome Sequences of Helicobacter pylori Clarithromycin-Resistant Strains. Genome Announc 2013;1:e00912-13. [PMID: 24233587 DOI: 10.1128/genomeA.00912-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
414 Eisig JN, Navarro-rodriguez T, Teixeira ACS, Silva FM, Mattar R, Chinzon D, Haro C, Diniz MA, Moraes-filho JP, Fass R, Barbuti RC. Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial. Gastroenterology Research and Practice 2015;2015:1-5. [DOI: 10.1155/2015/818043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
415 Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. Journal of Pediatric Gastroenterology & Nutrition 2017;64:e56-60. [DOI: 10.1097/mpg.0000000000001257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
416 Alfaresi MS, Elkoush AA. Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE. Indian J Gastroenterol. 2010;29:116-120. [PMID: 20658326 DOI: 10.1007/s12664-010-0034-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
417 Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. J Clin Microbiol. 2019;57:pii: e01834-18. [PMID: 31068413 DOI: 10.1128/jcm.01834-18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 8.5] [Reference Citation Analysis]
418 Kim SY, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple “concomitant” therapy and 7-day standard triple therapy. J Clin Gastroenterol. 2013;47:21-24. [PMID: 22647826 DOI: 10.1097/mcg.0b013e3182548ad4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
419 Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother. 2012;18:848-852. [PMID: 22581031 DOI: 10.1007/s10156-012-0425-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
420 Yuan W, Li Yumin, Yang Kehu, Ma Bin, Guan Quanlin, Wang D, Yang L. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45:665-676. [PMID: 20201716 DOI: 10.3109/00365521003663670] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
421 Alam MI, Paget T, Elkordy A. Characterization of furazolidone-chitosan based spray dried microparticles regarding their drug release and mucin adsorptive properties. Powder Technology 2016;295:175-9. [DOI: 10.1016/j.powtec.2016.03.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
422 Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019;25:4629-60. [PMID: 31528091 DOI: 10.3748/wjg.v25.i32.4629] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 26.0] [Reference Citation Analysis]
423 Tonkić A, Tonkić M, Barišić IG, Jukić I, Miše S. Antibiotic resistance of Helicobacter pylori isolated in Split, Southern Croatia. International Journal of Antimicrobial Agents 2005;25:449-50. [DOI: 10.1016/j.ijantimicag.2005.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
424 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
425 Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343-357. [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x] [Cited by in Crossref: 220] [Cited by in F6Publishing: 203] [Article Influence: 15.7] [Reference Citation Analysis]
426 Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007;26:495-500. [PMID: 17635384 DOI: 10.1111/j.1365-2036.2007.03384.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
427 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
428 Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J 2019;18:644-52. [PMID: 31611747 DOI: 10.17179/excli2019-1613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
429 Mégraud F. Helicobacter pylori : caractères bactériologiques, méthodes diagnostiques et sensibilité aux antibiotiques. La Presse Médicale 2008;37:507-12. [DOI: 10.1016/j.lpm.2007.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
430 Abadi AT, Taghvaei T, Ghasemzadeh A, Mobarez AM. High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran. Saudi J Gastroenterol. 2011;17:396-399. [PMID: 22064338 DOI: 10.4103/1319-3767.87181] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
431 Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;15:460-466. [PMID: 21083752 DOI: 10.1111/j.1523-5378.2010.00788.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 9.1] [Reference Citation Analysis]
432 Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
433 Saleem A, Qasim A, O’Connor HJ, O’Morain CA. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther. 2009;7:793-799. [PMID: 19735221 DOI: 10.1586/eri.09.55] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
434 Silva GM, Silva HM, Nascimento J, Gonçalves J, Pereira F, Lima R. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter 2018;23:e12528. [DOI: 10.1111/hel.12528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
435 Llanes R, Soria C, Nagashima S, Kobayashi N, Gala A, Guzmán D, Feliciano O, Valdés L, Gutiérrez O, Fernández H, Llop A, Wada A. Phenotypic and genetic characterization of antimicrobial profiles of Helicobacter pylori strains in Cuba. J Health Popul Nutr 2010;28:124-9. [PMID: 20411674 DOI: 10.3329/jhpn.v28i2.4881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
436 Peretz A, Paritsky M, Nasser O, Brodsky D, Glyatman T, Segal S, On A. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. J Antibiot 2014;67:555-7. [DOI: 10.1038/ja.2014.38] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
437 Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal of Global Antimicrobial Resistance 2017;10:182-5. [DOI: 10.1016/j.jgar.2017.05.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
438 Vakil N, Megraud F. Eradication Therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. [DOI: 10.1053/j.gastro.2007.07.008] [Cited by in Crossref: 154] [Cited by in F6Publishing: 147] [Article Influence: 11.0] [Reference Citation Analysis]
439 Marques AT, Vítor JMB, Santos A, Oleastro M, Vale FF. Trends in Helicobacter pylori resistance to clarithromycin: from phenotypic to genomic approaches. Microb Genom 2020;6. [PMID: 32118532 DOI: 10.1099/mgen.0.000344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
440 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. [PMID: 17170018 DOI: 10.1136/gut.2006.101634] [Cited by in Crossref: 1222] [Cited by in F6Publishing: 1065] [Article Influence: 81.5] [Reference Citation Analysis]
441 Megraud F. Helicobacter pylori and antibiotic resistance. Gut. 2007;56:1502. [PMID: 17938430 DOI: 10.1136/gut.2007.132514] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
442 Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, Wex T, Tammer I, Schlüter D, Malfertheiner P. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol. 2013;25:1257-1260. [PMID: 23863261 DOI: 10.1097/meg.0b013e3283643491] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
443 Prazeres VFV, Tizón L, Otero JM, Guardado-calvo P, Llamas-saiz AL, van Raaij MJ, Castedo L, Lamb H, Hawkins AR, González-bello C. Synthesis and Biological Evaluation of New Nanomolar Competitive Inhibitors of Helicobacter pylori Type II Dehydroquinase. Structural Details of the Role of the Aromatic Moieties with Essential Residues. J Med Chem 2010;53:191-200. [DOI: 10.1021/jm9010466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
444 Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. Intern Med 2017;56:1277-85. [PMID: 28566587 DOI: 10.2169/internalmedicine.56.7833] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
445 Kaya AD, Oztürk CE, Akcan Y, Behçet M, Karakoç AE, Yücel M, Mısırlıoglu M, Tuncer S. Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. Curr Ther Res Clin Exp 2007;68:151-60. [PMID: 24683206 DOI: 10.1016/j.curtheres.2007.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
446 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. [PMID: 17170018 DOI: 10.1036/gut.2006.101634] [Reference Citation Analysis]
447 Pastukh N, Peretz A, Brodsky D, Isakovich N, Azrad M, On A. Antimicrobial susceptibility of Helicobacter pylori strains isolated from children in Israel. Journal of Global Antimicrobial Resistance 2018;12:175-8. [DOI: 10.1016/j.jgar.2017.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
448 Qureshi NN, Gallaher B, Schiller NL. Evolution of amoxicillin resistance of Helicobacter pylori in vitro: Characterization of resistance mechanisms. Microb Drug Resist. 2014;20:509-516. [PMID: 24901497 DOI: 10.1089/mdr.2014.0019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
449 Yakoob J, Abbas Z, Usman MW, Awan S, Naz S, Jafri F, Hamid S, Jafri W. Comparison of Antimicrobial Activity of Zinc Chloride and Bismuth Subsalicylate Against Clinical Isolates of Helicobacter pylori. Microbial Drug Resistance 2014;20:305-9. [DOI: 10.1089/mdr.2013.0086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
450 Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012;67:170-173. [PMID: 21965436 DOI: 10.1093/jac/dkr410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
451 Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol. 2012;27:498-503. [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
452 Farshad S, Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee P, Amin Shahidi M, Hosseini M. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol 2010;16:5746-51. [PMID: 21128326 DOI: 10.3748/wjg.v16.i45.5746] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
453 Strausbaugh LJ, Siegel JD, Weinstein RA, Weinstein RA. Preventing Transmission of Multidrug-Resistant Bacteria in Health Care Settings: A Tale of Two Guidelines. Clinical Infectious Diseases 2006;42:828-35. [DOI: 10.1086/500408] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
454 Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012;7:447-452. [PMID: 21437583 DOI: 10.1007/s11739-011-0563-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
455 Manyi-Loh CE, Clarke AM, Ndip RN. Detection of phytoconstituents in column fractions of n-hexane extract of Goldcrest honey exhibiting anti-Helicobacter pylori activity. Arch Med Res. 2012;43:197-204. [PMID: 22560982 DOI: 10.1016/j.arcmed.2012.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
456 Li H, Yang T, Tang H, Tang X, Shen Y, Benghezal M, Tay A, Marshall B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precision Clinical Medicine 2019;2:77-80. [DOI: 10.1093/pcmedi/pbz009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
457 Lins AK, Lima RA, Magalhães M. Clarithromycin-resistant Helicobacter pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction. Arq Gastroenterol 2010;47:379-82. [PMID: 21225149 DOI: 10.1590/s0004-28032010000400011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
458 Lee JH, Ahn JY, Choi KD, Jung HY, Kim JM, Baik GH, Kim BW, Park JC, Jung HK, Cho SJ, Shin CM, Choi YJ, Lee SH, Kim JH, Lee WS, Sung JK, Chung JW, Cheung DY, Lee H, Min YW, Kim JJ, Kim SY;  Korean College of Helicobacter;  Upper Gastrointestinal Research. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter. 2019;24:e12592. [PMID: 31111572 DOI: 10.1111/hel.12592] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
459 Mégraud F. Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr Infect Dis Rep 2005;7:115-20. [PMID: 15727738 DOI: 10.1007/s11908-005-0071-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
460 Kotiw M, Johnson M, Pandey M, Fry S, Hazell SL, Netter HJ, Good MF, Olive C. Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model. Clin Vaccine Immunol 2012;19:268-76. [PMID: 22205658 DOI: 10.1128/CVI.05295-11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
461 Kim JH. Recent Update on Third-line Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2015;15:89. [DOI: 10.7704/kjhugr.2015.15.2.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
462 Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20:280-322. [PMID: 17428887 DOI: 10.1128/cmr.00033-06] [Cited by in Crossref: 385] [Cited by in F6Publishing: 175] [Article Influence: 27.5] [Reference Citation Analysis]
463 Lopo I, Libânio D, Pita I, Dinis-ribeiro M, Pimentel-nunes P. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018;23:e12493. [DOI: 10.1111/hel.12493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
464 Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;:CD009034. [PMID: 27351542 DOI: 10.1002/14651858.CD009034.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
465 Ben Mansour K, Burucoa C, Zribi M, Masmoudi A, Karoui S, Kallel L, Chouaib S, Matri S, Fekih M, Zarrouk S, Labbene M, Boubaker J, Cheikh I, Hriz MB, Siala N, Ayadi A, Filali A, Mami NB, Najjar T, Maherzi A, Sfar MT, Fendri C. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: A prospective multicentre study. Ann Clin Microbiol Antimicrob. 2010;9:22. [PMID: 20707901 DOI: 10.1186/1476-0711-9-22] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
466 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
467 Gisbert JP, Pérez-Aisa A, Castro-Fernández M, Barrio J, Rodrigo L, Cosme A, Gisbert JL, Marcos S, Moreno-Otero R. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287-290. [PMID: 19632166 DOI: 10.1016/j.dld.2009.06.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
468 Ndip RN, Malange Takang AE, Ojongokpoko JE, Luma HN, Malongue A, Akoachere JF, Ndip LM, MacMillan M, Weaver LT. Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: Current status of antibiogram. Trop Med Int Health. 2008;13:848-854. [PMID: 18384477 DOI: 10.1111/j.1365-3156.2008.02062.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
469 Zhang X, Jiang A, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability. Molecules 2016;21:E1435. [PMID: 27801837 DOI: 10.3390/molecules21111435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
470 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
471 Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter. 2011;16:47-51. [PMID: 21241412 DOI: 10.1111/j.1523-5378.2010.00816.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
472 Metters JP, Kampouris DK, Banks CE. Electrochemistry provides a point-of-care approach for the marker indicative of Pseudomonas aeruginosa infection of cystic fibrosis patients. Analyst 2014;139:3999-4004. [DOI: 10.1039/c4an00675e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
473 Kim JY, Kim NY, Kim SJ, Baik GH, Kim GH, Kim JM, Nam RH, Kim HB, Lee DH, Jung HC, Song IS. [Regional difference of antibiotic resistance of helicobacter pylori strains in Korea]. Korean J Gastroenterol 2011;57:221-9. [PMID: 21519175 DOI: 10.4166/kjg.2011.57.4.221] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
474 Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. J Korean Med Sci. 2014;29:1240-1246. [PMID: 25246742 DOI: 10.3346/jkms.2014.29.9.1240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
475 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357. [PMID: 17566020 DOI: 10.1038/gut.2007.125658] [Reference Citation Analysis]
476 Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. Helicobacter. 2011;16:356-362. [PMID: 21923681 DOI: 10.1111/j.1523-5378.2011.00856.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
477 de Jonge BL, Kutschke A, Newman JV, Rooney MT, Yang W, Cederberg C. Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy. Antimicrob Agents Chemother 2015;59:2337-42. [PMID: 25645840 DOI: 10.1128/AAC.04410-14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
478 Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
479 Hitzler I, Oertli M, Becher B, Agger EM, Müller A. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology. 2011;141:186-96, 196.e1. [PMID: 21569773 DOI: 10.1053/j.gastro.2011.04.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
480 Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2013;37:1165-1171. [PMID: 23656465 DOI: 10.1111/apt.12329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
481 Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother. 2009;63:648-653. [PMID: 19190100 DOI: 10.1093/jac/dkp003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
482 Narayana JL, Huang HN, Wu CJ, Chen JY. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model. Biomaterials. 2015;61:41-51. [PMID: 25996410 DOI: 10.1016/j.biomaterials.2015.05.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
483 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
484 Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. The Lancet Infectious Diseases 2006;6:699-709. [DOI: 10.1016/s1473-3099(06)70627-2] [Cited by in Crossref: 193] [Cited by in F6Publishing: 64] [Article Influence: 12.9] [Reference Citation Analysis]
485 Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017;32:589-594. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
486 Vaira D, Ricci C, Lanzini A, Perna F, Romano A, Corinaldesi R. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy. Dig Dis. 2007;25:203-205. [PMID: 17827940 DOI: 10.1159/000103885] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
487 Hsu P, Tsay F, Kao JY, Peng N, Tsai K, Tsai T, Kuo C, Kao S, Wang H, Chen Y, Shie C, Wu D; Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium. Equivalent efficacies of reverse hybrid and concomitant therapies in first‐line treatment of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2020;35:1731-7. [DOI: 10.1111/jgh.15034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
488 O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009;33:801-19. [PMID: 19416364 DOI: 10.1111/j.1574-6976.2009.00176.x] [Cited by in Crossref: 167] [Cited by in F6Publishing: 131] [Article Influence: 13.9] [Reference Citation Analysis]
489 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014;20:5283-5293. [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 45] [Article Influence: 10.2] [Reference Citation Analysis]
490 Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016. [PMID: 16916269 DOI: 10.1517/13543784.15.9.995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
491 Zullo A, Perna F, Ricci C, Hassan C, Tampieri A, De Francesco V, Morini S, Vaira D. 13C-urea breath test values and Helicobacter pylori eradication. Dig Dis Sci. 2008;53:370-374. [PMID: 17597398 DOI: 10.1007/s10620-007-9893-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
492 Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130. [PMID: 16699270 DOI: 10.1159/000090315] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
493 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021:gutjnl-2021-324032. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
494 Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 2013;68:222-228. [PMID: 22984204 DOI: 10.1093/jac/dks361] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
495 Gisbert JP, Calvet X, O'connor JA, Mégraud F, O'morain CA. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opinion on Pharmacotherapy 2010;11:905-18. [DOI: 10.1517/14656561003657152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
496 Ma HJ, Wang JL. Quadruple therapy for eradication of Helicobacter pylori. World J Gastroenterol. 2013;19:931-935. [PMID: 23429422 DOI: 10.3748/wjg.v19.i6.931] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
497 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 11.8] [Reference Citation Analysis]
498 Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796-1803. [PMID: 24648504 DOI: 10.1093/jac/dku050] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
499 Andrews PC, Ferrero RL, Forsyth CM, Junk PC, Maclellan JG, Peiris RM. Bismuth(III) Saccharinate and Thiosaccharinate Complexes and the Effect of Ligand Substitution on Their Activity against Helicobacter pylori. Organometallics 2011;30:6283-91. [DOI: 10.1021/om2008869] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
500 Luo XF, Jiao JH, Zhang WY, Pu HM, Qu BJ, Yang BY, Hou M, Ji MJ. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. World J Gastroenterol 2016;22:5822-30. [PMID: 27433095 DOI: 10.3748/wjg.v22.i25.5822] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
501 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 204] [Article Influence: 91.3] [Reference Citation Analysis]
502 Coelho LGV, Moretzsohn LD, Vieira WLS, Gallo MA, Passos MCF, Cindr JM, Cerqueira MC, Vitiello L, Ribeiro ML, Mendonca S, Pedrazzoli-junior J, Castro LP. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005;21:783-7. [DOI: 10.1111/j.1365-2036.2005.02370.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
503 Agudo S, Alarcón T, Urruzuno P, Martínez MJ, López-Brea M. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. Diagn Microbiol Infect Dis. 2010;67:213-219. [PMID: 20542201 DOI: 10.1016/j.diagmicrobio.2010.02.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
504 Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441-445. [PMID: 16961806 DOI: 10.1111/j.1523-5378.2006.00436.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
505 Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009;104:21-25. [PMID: 19098844 DOI: 10.1038/ajg.2008.87] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.9] [Reference Citation Analysis]
506 Severi C, Abdullahi M, Tari R, Vannella L, Marcheggiano A, Capoccia D, Leonetti F, Osborn J, Annibale B. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. Digestive and Liver Disease 2009;41:555-8. [DOI: 10.1016/j.dld.2008.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
507 De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis. 2011;32:787-795. [PMID: 21436188 DOI: 10.1093/carcin/bgr054] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
508 Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013;4:43-46. [PMID: 23946886 DOI: 10.4291/wjgp.v4.i3.43] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
509 Zhang L, Zhang L, Deng H, Li H, Tang W, Guan L, Qiu Y, Donovan MJ, Chen Z, Tan W. In vivo activation of pH-responsive oxidase-like graphitic nanozymes for selective killing of Helicobacter pylori. Nat Commun 2021;12:2002. [PMID: 33790299 DOI: 10.1038/s41467-021-22286-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
510 Nakamura A, Furuta T, Shirai N, Sugimoto M, Kajimura M, Soya Y, Hishida A. Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method. J Gastroenterol Hepatol. 2007;22:1057-1063. [PMID: 17608851 DOI: 10.1111/j.1440-1746.2006.04546.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
511 Calvet X, Gisbert JP, Suarez D. Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view. Helicobacter. 2011;16:346-355. [PMID: 21923680 DOI: 10.1111/j.1523-5378.2011.00890.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
512 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
513 Doorakkers E, Lagergren J, Gajulapuri VK, Callens S, Engstrand L, Brusselaers N. Helicobacter pylori eradication in the Swedish population. Scandinavian Journal of Gastroenterology 2017;52:678-85. [DOI: 10.1080/00365521.2017.1303844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
514 Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861. [PMID: 23537368 DOI: 10.1517/14656566.2013.782286] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 6.9] [Reference Citation Analysis]
515 Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C;  HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
516 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol. 2014;5:392-399. [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
517 O’Connor A, O’Moráin C. Helicobacter pylori infection in Europe: current perspectives. Expert Rev Gastroenterol Hepatol. 2013;7:541-548. [PMID: 23985003 DOI: 10.1586/17474124.2013.824707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
518 Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, Yoon H, Hwang JH, Jeoung SH, Kim JW. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014;29:1171-1176. [PMID: 24955448 DOI: 10.1111/jgh.12518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
519 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
520 Ge X, Cai Y, Chen Z, Gao S, Geng X, Li Y, Jia J, Sun Y. Bifunctional Enzyme SpoT Is Involved in Biofilm Formation of Helicobacter pylori with Multidrug Resistance by Upregulating Efflux Pump Hp1174 (gluP). Antimicrob Agents Chemother. 2018;62. [PMID: 30181372 DOI: 10.1128/aac.00957-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
521 Lahbabi M, Loukili B, Berreho A, Tachfouti N, Elyousfi M, Mellouki I, Aqodad N, Elabkari M, Elrhazi K, Nejjari C, Benajah D, Ibrahimi A. Éradication d’H. pylori dans les ulcères bulbaires: quelle trithérapie de première intention? Résultats d’une étude prospective randomisée comparant le métronidazole à la clarithromycine. J Afr Hepato Gastroenterol 2012;6:18-23. [DOI: 10.1007/s12157-011-0338-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
522 Zambon CF, Fasolo M, Basso D, D'Odorico A, Stranges A, Navaglia F, Fogar P, Greco E, Schiavon S, Padoan A, Fadi E, Sturniolo GC, Plebani M, Pedrazzoli S. Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J Gastrointest Surg 2007;11:1506-14; discussion 1514. [PMID: 17846855 DOI: 10.1007/s11605-007-0246-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
523 Graham DY, Kudo M, Reddy R, Opekun AR. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter. 2005;10:1-3. [PMID: 15691309 DOI: 10.1111/j.1523-5378.2005.00285.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
524 Zhao S, Lv Y, Zhang JB, Wang B, Lv GJ, Ma XJ. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori. World J Gastroenterol 2014;20:9321-9. [PMID: 25071326 DOI: 10.3748/wjg.v20.i28.9321] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
525 Mégraud F, Alix C, Charron P, Bénéjat L, Ducournau A, Bessède E, Lehours P. Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter 2021;26:e12767. [PMID: 33090614 DOI: 10.1111/hel.12767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Cerqueira RM, Correia MR, Vilar H, Manso MC. How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? OBES SURG 2016;26:1163-6. [DOI: 10.1007/s11695-015-1920-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
527 Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73. [PMID: 19755966 DOI: 10.1038/ajg.2009.508] [Cited by in Crossref: 133] [Cited by in F6Publishing: 113] [Article Influence: 11.1] [Reference Citation Analysis]
528 Velin D, Michetti P. Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol. 2010;4:157-166. [PMID: 20350263 DOI: 10.1586/egh.10.6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]